HCV Treatment
New HCV Protease Inhibitor ACH-2684 Looks Good in Phase 1 Study
- Details
- Category: HCV Treatment
- Published on Friday, 08 June 2012 00:00
- Written by Achillion Pharmaceuticals
Achillion's next-generation hepatitis C virus (HCV) protease inhibitor ACH-2684 appeared safe and reduced HCV viral load by up to 4.16 log after 3 days of monotherapy in a Phase 1 of healthy volunteers and people with genotype 1 chronic hepatitis C, the company reported last month.
Hepatitis C Treatment Reduces HIV Progression and Death in HIV/HCV Coinfected
- Details
- Category: HCV Treatment
- Published on Tuesday, 05 June 2012 00:00
- Written by Liz Highleyman
HIV positive people who achieve sustained virological response (SVR) to interferon-based therapy for chronic hepatitis C not only lower their risk of liver-related complications and death, but also have lower rates of HIV disease progression and all-cause mortality, according to a study published in the May 18, 2012, advance online edition of Clinical Infectious Diseases.
EASL 2012: Ribavirin Dose Reduction Is Effective for Managing Anemia in Patients Using Boceprevir or Telaprevir
- Details
- Category: HCV Treatment
- Published on Tuesday, 08 May 2012 00:00
- Written by Liz Highleyman
Reducing the dose of ribavirin and adding erythropoietin are both good options for managing anemia in hepatitis C patients treated with boceprevir (Victrelis) triple therapy, according to study findings presented at the 47th International Liver Congress (EASL 2012) this week in Barcelona. A related study found that ribavirin reduction also did not impair cure rates with telaprevir (Incivek).
EASL 2012: Telaprevir 100% Effective for IL28B CC, Adding VX-222 Overcomes Unfavorable Genes
- Details
- Category: HCV Treatment
- Published on Wednesday, 23 May 2012 00:00
- Written by Liz Highleyman
Adding telaprevir (Incivek) to pegylated interferon and ribavirin cured all hepatitis C patients with the favorable IL28B gene pattern, researchers reported at the 47th International Liver Congress (EASL 2012) last month in Barcelona. Another study found that adding the experimental HCV polymerase inhibitor VX-222 raised cure rates even for those with unfavorable IL28B patterns.
EASL 2012: MicroRNA Miravirsen Looks Safe and Effective for Genotype 1 Hepatitis C
- Details
- Category: HCV Treatment
- Published on Friday, 04 May 2012 00:00
- Written by Liz Highleyman
Miravirsen, the first microRNA therapy for hepatitis C, was well-tolerated and demonstrated prolonged antiviral activity lasting past the end of dosing in a proof-of-concept study of previously untreated HCV genotype 1 patients presented at the 47th International Liver Congress (EASL 2012) last month in Barcelona.
More Articles...
- EASL 2012: BI 201335 + BI 207127 + Ribavirin Shows Good Efficacy, Including Hepatitis C Patients with Cirrhosis
- EASL 2012: Promising Findings for Therapeutic Hepatitis C Vaccine TG4040
- EASL 2012: Boceprevir a Useful Option for Patients Who Did Not Respond to Earlier Hepatitis C Therapy
- EASL 2012: Abbott Interferon-Free HCV Combinations Show Early Promise for Untreated Patients
Web Design and Development by